Literature DB >> 8443147

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.

J E Hokanson1, M A Austin, A Zambon, J D Brunzell.   

Abstract

Familial combined hyperlipidemia (FCHL) is a genetic disorder characterized by increases in plasma cholesterol and/or triglyceride, elevated apolipoprotein B, and heterogeneous low density lipoprotein (LDL). To examine the relation between plasma triglyceride concentrations and LDL heterogeneity, 13 hypertriglyceridemic FCHL patients with a predominance of small LDL (LDL subclass phenotype B) were treated with gemfibrozil. The distribution of LDL was determined using nondenaturing gradient gel electrophoresis and nonequilibrium density gradient ultracentrifugation. Mean plasma triglyceride levels decreased 55% (p < 0.01) after 3 months of treatment. Mean LDL peak particle size remained small (247 +/- 4 versus 249 +/- 5 A), and the correlation between change in plasma triglyceride concentrations and a change in LDL peak particle size was not significant. Individual changes in LDL flotation rate (Rf) were, however, inversely correlated with changes in triglyceride concentration (R = 0.60, p < 0.05). Although mean LDL Rf increased during treatment (p < 0.005) due to an increase in buoyant LDL, dense LDL remained elevated compared with that of a control population. Thus in FCHL patients, small, dense LDL persists despite decreases in plasma triglyceride concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443147     DOI: 10.1161/01.atv.13.3.427

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  9 in total

1.  Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.

Authors:  S J Bredie; L A Kiemeney; A F de Haan; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

2.  Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families.

Authors:  Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik
Journal:  Hum Genet       Date:  2010-04-11       Impact factor: 4.132

3.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

4.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

Authors:  S H Juo; S J Bredie; L A Kiemeney; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

5.  Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI.

Authors:  Sara Bretschger Seidelmann; Lin Li; Gong-Qing Shen; Eric J Topol; Qing Kenneth Wang
Journal:  J Lipid Res       Date:  2008-01-31       Impact factor: 5.922

Review 6.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment.

Authors:  Inka Miñambres; Jose Luis Sánchez-Quesada; Joan Sánchez-Hernández; Jose Rodríguez; Alberto de Leiva; Antonio Pérez
Journal:  Diabetol Metab Syndr       Date:  2014-01-22       Impact factor: 3.320

8.  Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate.

Authors:  Arrigo F G Cicero; Giuseppe Derosa; Pamela Maffioli; Alessandra Reggi; Elisa Grandi; Claudio Borghi
Journal:  Arch Med Sci       Date:  2013-04-09       Impact factor: 3.318

Review 9.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

Authors:  Antonio Gaddi; A F G Cicero; F O Odoo; A A Poli; R Paoletti
Journal:  Vasc Health Risk Manag       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.